AIM ImmunoTech Inc reveals positive pilot study data from EAP evaluating Ampligen for treatment of Long COVID
AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating...